Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Intuitive Surgical's Q3 2026 results — the robotic surgery giant behind the da Vinci system.

**ALEX:** Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good to have that out of the way. And Alex, this was a packed quarter — big numbers, a major legal settlement, pricing strategy shifts, even a new factory announcement in Malaysia.

**ALEX:** Let's start with the headline numbers. Revenue grew 22% year-over-year to just over $3 billion, with 84% of that being recurring revenue — which, as always, is the magic of Intuitive's razor-and-blade business model.

**JORDAN:** Right, and non-GAAP EPS grew 25% to $3 per share. Operating margin came in at 42%, or 41% if you strip out a one-time tariff refund. That's genuinely elite profitability for medtech.

**ALEX:** But here's the asterisk — GAAP net income actually fell to $523 million, down from $704 million a year ago. Why the disconnect?

**JORDAN:** That's the $450 million litigation settlement. Intuitive reached a no-fault agreement with customers in a class action lawsuit over third-party instrument remanufacturing and servicing. It's subject to court approval, expected sometime next year, but they took the charge now.

**ALEX:** So basically, they're paying to put a messy legal issue behind them and get certainty on how they work with hospitals going forward.

**JORDAN:** Exactly — CEO Dave Rosa framed it as removing a distraction so they can focus on advancing product safety and quality rather than litigating.

**ALEX:** Let's talk procedures, because that's really the heartbeat of this business. Total procedures grew 15%, da Vinci procedures up 14%, and Ion — that's their lung biopsy platform — up a blazing 31%.

**JORDAN:** The geographic split is interesting too. International da Vinci growth was 20%, while U.S. growth was 10% — and that 10% actually drew some pointed analyst questions on the call.

**ALEX:** Yeah, an analyst from Wells Fargo flagged that 10% as the slowest U.S. growth since COVID. What was management's response?

**JORDAN:** Dave Rosa basically said: don't panic, it's a tough comp — last year's Q3 grew 16%, their hardest comparison of the year. CFO Jamie Samath added more color, saying they're leaning into four growth levers: adding system capacity, especially for benign general surgery; pushing into ambulatory surgery centers, where ASC placements doubled over just two quarters; developing cardiac and breast procedures as emerging categories; and new indications in the R&D pipeline.

**ALEX:** And speaking of placements — system placements overall were strong. 546 da Vinci systems placed globally, up 28%. The da Vinci 5, their newest platform, now makes up 65% of global placements combined with the single-port system.

**JORDAN:** They've crossed 2,000 da Vinci 5 systems installed worldwide, used by over 18,000 surgeons. That's real traction for a platform that's still relatively new.

**ALEX:** Now let's get into the pricing story, because this is a genuine strategic shift. Intuitive announced they're cutting instrument pricing on high-volume "benign" procedures — think hernia repairs, gallbladder removals, hysterectomies — stuff where laparoscopy has dominated because it's cheaper.

**JORDAN:** They're extending the useful life of certain instruments and introducing volume-based pricing starting in 2027. The expected impact is a 3% to 5% reduction in da Vinci instrument-and-accessory revenue per procedure once fully rolled out.

**ALEX:** That sounds l

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.

**JORDAN:** And I'm Jordan. We've got a big one today — Danaher, ticker DHR, reporting Q3 2026 results, plus a new CEO laying out her vision for the company's "next chapter."

**ALEX:** Lots to dig into. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Important stuff, now let's get into it. Alex, this quarter actually beat expectations across the board.

**ALEX:** It did. Revenue came in at $6.6 billion. Core revenue growth, excluding respiratory products, was 5.5% — that's a 100 basis point acceleration from Q2. Adjusted EPS was $2.11, up about 11.5% year-over-year. And free cash flow? $1.6 billion in the quarter alone.

**JORDAN:** And that cash flow number matters — year-to-date free cash flow to net income conversion was 128%. That's a sign of genuinely high-quality earnings, not just accounting magic.

**ALEX:** Right. Now, there's a wrinkle here — respiratory diagnostics, think flu and COVID testing, has been a drag all year because infection rates are just lower than prior years. That category was about a 250 basis point headwind in Q3. Strip that out, and the underlying business is clearly reaccelerating.

**JORDAN:** Segment-wise, Biotechnology grew 5%, with bioprocessing — basically equipment and consumables for manufacturing biologic drugs — coming in at the upper end of mid-single digits. Orders there grew mid-teens, which is a really encouraging forward indicator.

**ALEX:** Life Sciences grew 4.5%, third straight quarter beating internal expectations. And Diagnostics, excluding respiratory, was up 7%. Beckman Coulter Diagnostics had its best core growth quarter in over two years.

**JORDAN:** Geographically, high-growth markets were the story — up about 10%, with China up high-single digits across all three segments. Developed markets were basically flat, with North America dragged down mostly by that respiratory decline.

**ALEX:** On guidance — Danaher raised full-year adjusted EPS guidance to $8.57 to $8.62, up from $8.45 to $8.60. Q4 core growth ex-respiratory is expected at 4% to 5%, with operating margin around 29.5%.

**JORDAN:** And they gave us an early look at 2027 — suggesting that same 4-5% core growth rate ex-respiratory as a starting point. A few analysts on the call pushed back on that, honestly. Given strong bioprocessing orders, easing China headwinds, and recovering biotech funding, why isn't the number higher?

**ALEX:** Yeah, that was Tycho Peterson from Jefferies basically saying "show me the acceleration." Management's answer was essentially: we want to get through our Q4 planning process before committing to anything more specific, formal guidance comes in January.

**JORDAN:** Fair, but it does leave a little tension in the air — is this conservatism, or is something softer under the hood? I'd lean toward conservatism given the order trends they's describing, but it's worth watching.

**ALEX:** Now let's talk strategy, because this call was really about new CEO Julie Sawyer Montgomery setting her agenda. She's a Danaher veteran — nine years at the company — stepping into the top role for the first time this quarter.

**JORDAN:** She laid out four priorities: commercial excellence, innovation, talent, and disciplined capital allocation. The headline message was that Danaher's big portfolio transformation — becoming a pure-play Life Sciences and Diagnostics company — is basically done. Now it's about execution and growth, not reshaping the business.

**ALEX:** The phrase that stuck with me was "unambiguous share gain" — she used it multiple times as the real report card for success going forward.

**JORDAN

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.

**JORDAN:** And I'm Jordan. Alex, today we're digging into CME Group — ticker CME — Q3 2026 earnings. And spoiler alert: this one's a record-setter across the board.

**ALEX:** It really is. But before we jump in, our standard reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Appreciate you saying that, Alex. Okay, let's get into the numbers because they're genuinely impressive.

**ALEX:** So CME posted $1.7 billion in revenue, up 13% year-over-year — that's a record for a third quarter. Average daily volume hit 29.4 million contracts, up 16%, also a Q3 record. And here's the kicker: double-digit volume growth across all six asset classes. That's not one or two hot products carrying the quarter — that's genuinely broad-based strength.

**JORDAN:** Yeah, and when I see "broad-based," my analyst brain gets excited because it means the growth isn't fragile. Financial products up 16%, commodities up 16%, equities up 23% — equities actually led the pack. Adjusted operating income came in at $1.2 billion, up 15%, with a 69.4% operating margin. That's an incredibly efficient business model.

**ALEX:** And EPS — adjusted diluted earnings per share — was $3.02, up 13% from last year. Net income margin over 62%. For a company this size, those are eye-popping numbers.

**JORDAN:** One more highlight before we move on: market data revenue hit an all-time record at $243 million, up 20%. That's the 34th — count it, 34th — consecutive quarter of year-over-year growth in that segment. CME's data business just keeps compounding quietly in the background.

**ALEX:** It's almost become the unsung hero of this business. Okay, let's talk shareholder returns, because CME didn't just grow — they paid up. Nearly $1 billion returned to shareholders this quarter: $465 million in dividends, $524 million in buybacks.

**JORDAN:** And CEO Terry Duffy made a point of saying they've got one of the lowest debt loads in the sector, which gives them real flexibility — whether that's more buybacks, special dividends, or opportunistic M&A down the road.

**ALEX:** Speaking of flexibility, let's pivot to strategy, because there's a lot happening here. First up: the cloud migration with Google Cloud. They opened a Dallas disaster recovery facility, testing has gone well — latency's on par with their on-prem systems — and they're targeting late 2027 to start migrating markets to the cloud.

**JORDAN:** Interesting side note there — because the Dallas testing went so well, they decided they no longer need to physically relocate the livestock markets there. Small detail, but it shows the cloud infrastructure is doing exactly what they hoped.

**ALEX:** Then there's the new product pipeline. Single Stock futures launched and are off to a strong start — over 350,000 contracts traded, $3.5 billion in notional value since launch. They're getting traction both institutionally and on the retail side, working with over 130 retail firms.

**JORDAN:** What stood out to me in the Q&A was management's discipline around *not* rushing prediction markets onto everything. Terry Duffy was pretty blunt — he said just because there's a narrative that "every market needs a prediction market" doesn't make it true. They want Single Stock futures to establish themselves first before layering on anything else.

**ALEX:** That discipline theme came up again with the CFTC's Compute Futures review — that's the new contract tied to AI infrastructure and data center risk. Management's very bullish on client demand there, but it's sitting with regulators, comment period extended to November 9th. They're playing what Duffy called "the lon

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Chubb Limited's third quarter 2026 results — and this is a big insurance name with a lot of moving parts, so buckle up.

**JORDAN:** Lots to unpack here, Alex. Record numbers everywhere you look.

**ALEX:** Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good to have that on record. So let's get into it — Chubb, ticker CB, reported Q3 2026 earnings on October 21st.

**ALEX:** Right, and headline numbers: core operating income of $2.98 billion, or $7.66 per share. Now, that EPS figure was actually up about 1% year-over-year, but operating income itself was down 2% — and that's purely because last year's quarter had unusually light catastrophe losses. Easy comp issue, not a fundamental problem.

**JORDAN:** And honestly, the nine-month picture tells the real story. Core operating income of $8.6 billion, up 21% from last year. Core operating EPS of $21.94, up nearly 25%. That's a serious growth trajectory when you zoom out from the noisy quarterly comparisons.

**ALEX:** Underwriting was the real star here. P&C underwriting income came in at nearly $2.1 billion for the quarter, giving them a combined ratio of 84.1%. And get this — their ex-catastrophe combined ratio was 81.8%, basically flat year-over-year. For context, anything under 100 means they're making money on underwriting alone, before investment income even enters the picture. 81.8% is genuinely elite.

**JORDAN:** It's wild how consistent that discipline is. CEO Evan Greenberg has talked for years about being "slow to recognize favorable development, quick to recognize unfavorable" — basically, conservative reserving — and you see that show up in the numbers. Nine-month underwriting income hit a record $5.8 billion, up 34%.

**ALEX:** Now let's talk the investment side, because rates have been a huge tailwind here. Adjusted net investment income was a record $1.89 billion, up 6.3%. Their new money rate — meaning what they earn reinvesting maturing bonds — is now averaging 6.2%, compared to a portfolio yield of 5.2%. So every dollar that rolls over is earning more than before.

**JORDAN:** There was an interesting wrinkle too — rising rates created a $4.5 billion mark-to-market loss on their bond portfolio this quarter. But management was pretty clear that's an accounting artifact, not a real economic loss. Since they're buy-and-hold investors with a high-quality portfolio, that mark essentially "amortizes away" as bonds approach maturity.

**ALEX:** They also had a nice one-time win — their stake in USI Insurance Services, held through a partnership with KKR, is being sold to Aon. That's expected to produce a realized gain of $460 million on an original $740 million investment.

**JORDAN:** Not bad. Now, growth was a more nuanced story. Total P&C premiums were up just 1.9% — which sounds modest — but that masks some very different stories across the business. Overseas General, their international division, grew 6.7%. Personal lines in North America grew 5.3%. Agriculture was up over 5%.

**ALEX:** But North America Commercial actually declined 2.7%, and that's the piece analysts kept poking at during Q&A. Greenberg explained it's deliberate — they're walking away from property and financial lines business where pricing isn't adequate, and buying more reinsurance to lay off risk in those areas. He said that alone cost them about 4.5 points of growth.

**JORDAN:** And he was pretty direct that he expects North America Commercial growth to "improve materially in future quarters" — though when analysts pushed for specif

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

**JORDAN:** And I'm Jordan. We've got a genuinely big one today — Abbott Laboratories dropped some major news alongside their Q3 numbers.

**ALEX:** We'll get to that in a second, but first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** With that out of the way, Alex, let's start with the headline because it's not every day a 138-year-old company announces it's splitting itself in two.

**ALEX:** Right — Abbott announced it's spinning off its entire nutrition business into a standalone, publicly traded company by the end of 2027. We're talking about Similac, PediaSure, Ensure, Glucerna, Pedialyte — the whole $8.5 billion nutrition empire, 16,000 employees, 14 manufacturing sites. CEO Robert Ford said this would actually be the largest pure-play healthy nutrition company in the world, and they expect it to qualify for S&P 500 inclusion on its own.

**JORDAN:** And the CEO pick is interesting too — Daniel Salvadori, who's run their Established Pharma and Nutrition division, is taking the reins of the new company. Ford called his team "battle-tested," which, if you've followed Abbott's infant formula saga the last few years — recalls, litigation, supply shortages — that's not an exaggeration.

**ALEX:** The strategic logic here is basically: nutrition used to be a healthcare-professional-driven category, now it's a consumer wellness category, and those two worlds need different playbooks, different investment cycles, different marketing muscle. Ford's view is both companies do better focused and independent rather than living under one roof.

**JORDAN:** And for shareholders, it's structured as a tax-free spin — you'll own shares of both companies when it's done. Abbott's also planning to have the new nutrition company raise some debt, with proceeds flowing back to Abbott, and both companies will maintain investment-grade ratings.

**ALEX:** What's the math on what's left behind? Because that's really the investor question here.

**JORDAN:** Right, this is the key number. CFO Phil Boudreau said stripping nutrition out of the current portfolio, Abbott's remaining business — MedTech, Diagnostics, Established Pharma — would see sales growth accelerate by 50 to 100 basis points, gross margin expand by over 200 basis points, and operating margin up roughly 100 basis points. So the pitch is: a leaner, faster-growing, higher-margin Abbott emerges on the other side.

**ALEX:** Now let's talk actual Q3 results, because they were solid. Sales grew 7%, EPS grew 9% — both numbers accelerating from the first half of the year. Adjusted EPS came in at $1.42, right in line with guidance and consensus.

**JORDAN:** Breaking it down by segment — Diagnostics grew 6.5%, with Core Lab up 5.5% on strong demand across the U.S., Europe, Japan, and Latin America. But the real story there is Cancer Diagnostics, up 14%, largely thanks to the Exact Sciences integration — that's Cologuard. They also just launched their first blood-based colorectal cancer screening test in September, making Abbott the only company offering both stool-based and blood-based options.

**ALEX:** Nutrition — even as it heads for the exit — actually had a good quarter. Sales up 5%, broad-based across all four categories. Pediatric nutrition was the standout at 9% growth, helped by those WIC contract wins that let Abbott reclaim market leadership.

**JORDAN:** Medical Devices grew 8%, led by electrophysiology and rhythm management, both posting double-digit growth. The Volt PFA catheter is gaining serious traction after its

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: FAANG (https://betafinch.com/groups/FAANG)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're diving into Netflix's Q3 2026 earnings call. Lots to unpack here — new leadership, some ad business hiccups, and a theatrical strategy that's actually working.

**JORDAN:** Yeah, this was a meaty one. Before we get into it though...

**ALEX:** Right, gotta say it. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good, now let's get into it.

**ALEX:** So let's start with the numbers. Netflix hit its internal revenue targets this quarter and updated full-year guidance on revenue and margins. CFO Spence Neumann said all three of their growth levers — subscriber additions, pricing, and advertising — are firing. He's targeting double-digit revenue growth again heading into 2027, though he's holding off on specific guidance until the January call.

**JORDAN:** The thing that jumped out to me was churn. Both globally and in the U.S., churn improved year-over-year and came in better than forecast. That's the real tell here — when you raise prices and churn doesn't spike, that's a signal people still see Netflix as a must-have.

**ALEX:** Greg Peters actually had a great stat on that — he said U.S. Netflix subscribers are paying the least per hour of viewing compared to other streaming services, in some cases less than half what competitors charge for similar engagement. That's their pricing power argument in a nutshell.

**JORDAN:** But not everything was a clean win. Let's talk about advertising, because that's where things got a little more candid than usual.

**ALEX:** Yeah, so the ad business is growing over 80% year-over-year, which sounds great on its face...

**JORDAN:** It is great!

**ALEX:** It is. But management admitted they're behind their internal roadmap on rolling out new ad products and partner integrations. Peters basically said, "we set an aggressive target, and when you're aggressive, sometimes you miss milestones." It's refreshingly honest, but it's also why the stock had been a little jittery going into this call.

**JORDAN:** And there's still a real gap between what Netflix earns per ad-tier member versus a standard, ad-free subscriber. That gap is narrowing, but slowly. The bulls' takeaway: that gap represents future upside as the ad tech stack matures. The bears' takeaway: execution risk is real, and they're building this plane while flying it.

**ALEX:** Which brings us to a huge headline from this call — Peter Rice taking over as Chief Content Officer, replacing Bela Bajaria.

**JORDAN:** This is a big one. Ted Sarandos was effusive about Rice — a guy who's run TV networks, movie studios, and streaming platforms. The subtext here, though, is pretty clear: the international content slate is crushing it — India view hours up 24%, revenue up nearly 20% there alone — but the U.S. slate specifically isn't performing to its potential.

**ALEX:** Right, Sarandos was pretty direct: "It's not growing as fast as it could or as fast as we'd like." That's about as close to an admission of underperformance as you'll get on one of these calls.

**JORDAN:** And layering onto that — Netflix just announced its largest headcount reduction since 2022. Peters framed it as organizational discipline, trimming areas where they'd overbuilt, but combined with the content leadership shakeup, it does read like a company doing some internal recalibration even while growth numbers look healthy.

**ALEX:** Let's shift to something more fun — theatrical strategy, because this was a great moment in the call.

**JORDAN:** Oh, the box office reporting thing. So Netflix is now actually publicly repo

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Capital One's third quarter 2026 results. Ticker COF, and this is a big one because the Discover integration story is really starting to come into focus.

JORDAN: Lots to unpack today, Alex.

ALEX: Before we dive in, the standard reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, let's get into it. So, Capital One reported net income of $3.5 billion, or $5.61 per diluted share. But strip out the Discover and Brex acquisition-related adjustments, and that jumps to $6.69 adjusted EPS.

ALEX: And the growth story underneath that was pretty solid too. Revenue up 3% quarter over quarter, expenses actually down 2%, which gave them 10% growth in pre-provision earnings. That's the kind of operating leverage investors love to see.

JORDAN: Right, and credit was a bright spot. The domestic card charge-off rate came in at 3.98%, down 73 basis points from last quarter. CEO Rich Fairbank made a point of saying credit is "in a very good place" — delinquencies have been running roughly in line with seasonal norms rather than beating it the last few months, but the cumulative improvement over the past year has been significant.

ALEX: There was also this allowance release of $225 million, which helped the bottom line this quarter. Worth noting that's a bit of a one-time tailwind, not something to extrapolate forward every quarter.

JORDAN: Exactly. Now let's talk about the big strategic headline: Discover synergies. Capital One says they've achieved $1.8 billion in annualized combined synergies year-to-date — and they're hitting that ahead of schedule. A lot of that came from converting Capital One's debit business onto the Discover Network early in the year, plus disciplined expense management.

ALEX: That debit conversion piece is honestly the sleeper stat of the whole call. Global Payment Network transaction volume was up 25% year over year, hitting about $191 billion, almost entirely because of that successful migration.

JORDAN: And here's where it gets interesting for anyone trying to model out 2027. Fairbank basically gave investors a formula: take current run-rate earnings, adjust for the allowance release they've enjoyed this year, add back the marketing spend bump coming in Q4, then add the remaining synergies still to come — and subtract the expected hit from the Visa/MasterCard interchange settlement. His view? Those last two roughly cancel each other out.

ALEX: Which was his way of saying — you don't have to wait to "see" the earnings power of this deal. It's basically visible right now if you make those adjustments.

JORDAN: That Visa/MasterCard settlement note is important context too. It's heading through final court approval in November. Capital One says they're not waiting around — they've already baked a likely settlement into their planning, even though there's a wide error bar on the actual dollar impact.

ALEX: Let's talk about marketing, because this is where I think the forward narrative gets really interesting. Marketing spend was up 14% year-over-year this quarter to about $1.6 billion, and management flagged they're going to "lean harder" into marketing in 2027.

JORDAN: Three reasons stood out to me. One, they want to capture organic growth while the window's open. Two, competitors are spending heavily, so Capital One needs to keep pace. And three — this is the structural one — their fastest-growing segments, like the premium Venture X card business and the national bank, are just inherently more marketing-intensive businesses. Fairbank called it a "gradual mix shift."

ALEX: He also had this great line

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into RTX's third quarter 2026 results, and Alex, this one's got some big numbers.

ALEX: It really does. But before we jump in, quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Important stuff. Okay, let's get into it.

ALEX: So RTX — the parent company of Raytheon, Pratt & Whitney, and Collins Aerospace — reported adjusted sales of $25 billion for Q3, up 12% organically. That's growth across all three segments, which is pretty rare to see all firing at once.

JORDAN: And the EPS number really jumps out — $2.26, up 33% year-over-year. But here's the asterisk: $0.25 of that came from something called IEEPA cost recovery. That's basically tariff-related cost reimbursement, not pure operational performance.

ALEX: Right, so strip that out and you're still looking at really solid underlying growth — about 43 cents of that EPS gain came from actual segment operating profit improvement.

JORDAN: And free cash flow was strong too — $2.1 billion for the quarter. The company also raised full-year guidance across the board. New sales range is $97 to $97.5 billion, up from $95-96 billion. EPS guidance jumped to $7.65-$7.75, up from $7.10-$7.25.

ALEX: Now let's talk backlog, because this is the headline for me. $340 billion — up 36% year-over-year, 18% just sequentially. That's a massive number.

JORDAN: It's driven largely by defense. Raytheon booked almost $59 billion in awards this quarter alone — a book-to-bill ratio of 4.57 times. The big drivers were converting framework agreements into actual multi-year production contracts — about $23 billion for Tomahawk missiles and over $14 billion for AMRAAM.

ALEX: And they followed that up with multi-year contracts for SM-6 and SM-3 IIA missiles too. Management described this whole munitions push as converting nearly a decade's worth of demand visibility into firm contracts.

JORDAN: Which is great, but it comes with execution risk. CEO Christopher Calio talked about needing to ramp production 2x to 4x on some of these munitions. That means supply chain expansion, new suppliers — they added 150 new suppliers at Raytheon in 2025 alone — and working through bottlenecks like castings and solid rocket motors.

ALEX: Yeah, one analyst actually asked about printed circuit boards and capacitors being hard to source because of the AI data center buildout competing for the same components. Calio acknowledged it's a real constraint they're actively managing with the Department of Defense.

JORDAN: On the commercial side, let's talk Pratt & Whitney and the GTF engine story, because that's been the long-running saga for RTX.

ALEX: Right, the GTF — Geared Turbofan — has had durability issues for years that required extra maintenance checks. The good news this quarter: MRO output on the PW1100 engine was up 37% year-over-year, and critically, the GTF Advantage — the next-gen version with double the time-on-wing performance — just entered service with United Airlines.

JORDAN: That's a real milestone. And there's also a retrofit kit called Hot Section Plus coming next year that'll bring most of those durability benefits to the existing fleet without needing a whole new engine.

ALEX: Commercial aftermarket overall grew 16% organically, which is impressive given that global air traffic — RPKs — actually declined slightly. CFO Neil Mitchill noted about 60% of the Pratt Canada business jet fleet hasn't even had its first shop visit yet, so there's a long runway there.

JORDAN: Collins Aerospace also had a strong quarter — margins expanded 560 basis

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME), INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into 3M's third quarter 2026 results, reported October 20th. This is a loaded one, folks — strong numbers, a major Amazon partnership, and a lot of forward-looking commentary on 2027. Before we get into it, though, the standard reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And honestly, Alex, there's a lot to unpack here. 3M stock jumped over 5% on this print, so let's figure out why.

ALEX: Let's start with the headline numbers. Organic growth of 3.3% for the quarter, operating margin of 26.2% — up 110 basis points year-over-year — adjusted EPS of $2.50, up 12%, and free cash flow of $1.2 billion. They returned $600 million to shareholders, split between dividends and buybacks.

JORDAN: And importantly, they raised full-year EPS guidance to $9.10-$9.15, up from the prior range. That's roughly 11-12% growth for the year. Management also reaffirmed they expect organic growth above 3.5% for 2026, with Q4 actually accelerating to over 4%.

ALEX: That acceleration story is interesting because it's backed by real data — backlog was up high-teens year-over-year heading into Q4, and orders grew high single digits in the quarter. That's not just hopeful talk, that's visibility.

JORDAN: Right, and CFO Anurag Maheshwari broke down where the margin expansion is coming from — gross margins were up 230 basis points, driven by procurement savings, better quality control, and higher factory utilization. They've closed 16 manufacturing sites this year already, with 10 more targeted over the next year. That footprint simplification is expected to keep paying off well beyond 2027.

ALEX: Now let's get to the part everyone's been buzzing about — Expanded Beam Optical, or EBO. This is 3M's connector technology for AI data center infrastructure.

JORDAN: This is the big one. They filed an 8-K the night before the call announcing they issued Amazon a warrant for up to 3.2 million shares — about 0.6% of 3M's stock — tied to Amazon hitting $6 billion in cumulative purchases of optical connectivity and data-center-related products over seven years, plus other milestones.

ALEX: CEO Bill Brown was careful to frame this as strategic validation rather than a guaranteed revenue stream. He emphasized there's no firm volume commitment — 3M has to "earn the right" to that business. But symbolically, locking in a warrant structure with Amazon, on top of the previously announced Microsoft Azure partnership, signals real traction with hyperscalers.

JORDAN: And they paired that with a manufacturing deal — a contract agreement with Genius Electronic Optical, or GSEO, plus taking a 4.7% equity stake in that company to secure supply chain capacity. 3M's doubling its internal ferrule manufacturing capacity, and GSEO can reportedly scale multiples beyond that.

ALEX: Sizing it for listeners — EBO revenue this year is around $40 million. Management expects that to roughly double next year, maybe a bit more. They've pegged the total addressable market at around $2 billion by 2028. So it's small today, but the growth trajectory and the ecosystem-building — they mentioned a Multi-Source Agreement that's grown from 17 to 63 member companies — suggests this could become a meaningful growth vertical.

JORDAN: Let's talk segments for a second, because the picture is mixed. Safety & Industrial had a standout quarter, up 7% organically, driven by commercial excellence and new product ramp. Transportation & Electronics was basically flat at 0.5%, dragged down by co

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the transcripts so you don't have to. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're digging into General Motors' third quarter 2026 results, and there's a lot to unpack—record revenue, a massive new buyback, and a truck changeover that's about to shake things up.

**ALEX:** Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good to have that out of the way. Let's get into the numbers.

**ALEX:** So GM posted record third-quarter revenue of $50 billion, up 3% year-over-year. EBIT adjusted came in at $4.1 billion, up a strong 22%. And EPS diluted adjusted jumped more than 30% to $3.70.

**JORDAN:** Those EPS numbers really jump out when you consider share buybacks are doing a lot of heavy lifting there. GM's diluted share count is down 9% year-over-year, and since 2023 they've cut shares outstanding by 37%. That's a massive reduction.

**ALEX:** Which brings us to maybe the headline of the quarter—GM announced a brand new $20 billion multiyear share repurchase authorization. That's on top of completing their prior $6 billion program, which they actually wrapped up early in October.

**JORDAN:** Twenty billion is more than 25% of GM's current market cap. That's the board basically saying, "we think this stock is cheap, and we're going to keep buying it hand over fist." CFO Paul Jacobson even said they'll keep doing this "as long as the valuation remains depressed."

**ALEX:** North America margins were a bright spot too—8.7%, up two and a half points year-over-year. That puts them solidly back in their 8-10% target range after working through a lot of tariff pressure.

**JORDAN:** Right, and that's despite some real headwinds. Copper's at record highs, steel's at four-year highs, and GM said commodity, logistics, and DRAM memory costs added about $2 billion of pressure for the full year—more than they expected back in July.

**ALEX:** Let's talk about the truck changeover, because this is really the big operational story right now. GM is transitioning its light-duty Silverado and Sierra pickups to the next generation. Production just started at the Silao plant, with Fort Wayne following in Q1 and Orion launching in Q2 next year.

**JORDAN:** And that changeover isn't free. They're expecting about 35,000 fewer units in Q4 because of the downtime. But management's spinning it as short-term pain for long-term gain—better pricing and mix once the new trucks hit showrooms.

**ALEX:** Mary Barra was pretty bullish on the new trucks. New V8 and diesel engine options, a more premium High Country and Denali Ultimate trim strategy, and—this is the part I find interesting—Super Cruise is becoming standard on high-end trims. They expect full-size truck Super Cruise penetration to grow four to five times next year.

**JORDAN:** That software and services story is quietly becoming a real growth engine. OnStar and Super Cruise revenue was up 15% year-over-year this quarter, deferred revenue is up 40%, and they're approaching $7.5 billion in deferred revenue for the year. That's a high-margin business layered on top of the hardware.

**ALEX:** Now, on guidance—GM raised its full-year outlook again. EBIT adjusted now expected at $14.5 to $15.5 billion, up from $14-16 billion previously—so a narrower, higher range. Adjusted automotive free cash flow guidance jumped to $11.5-12.5 billion, up from $9.5-11.5 billion.

**JORDAN:** That free cash flow improvement is coming from a few places—lower capex than expected, some tariff refund timing benefits, and just strong operational execution. Worth noting, they've also made good progress working through those

This episode includes AI-generated content.